{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:29:22Z","timestamp":1794047362675,"version":"4.8.0"},"reference-count":13,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"4","license":[{"start":{"date-parts":[[2020,6,25]],"date-time":"2020-06-25T00:00:00Z","timestamp":1593043200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"DOI":"10.3324\/haematol.2020.253450","type":"journal-article","created":{"date-parts":[[2020,6,25]],"date-time":"2020-06-25T10:55:13Z","timestamp":1593082513000},"page":"1182-1187","source":"Crossref","is-referenced-by-count":24,"title":["Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed\/refractory multiple myeloma: ICARIA-MM subgroup analysis"],"prefix":"10.3324","volume":"106","author":[{"family":"Fredrik H. Schjesvold","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Paul G. Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Thierry Facon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Adri\u00e1n Alegre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Andrew Spencer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Artur Jurczyszyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Kazutaka Sunami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Laurent Frenzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Chang-Ki Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Sophie Guillonneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Peggy L. Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Solenn Le-Guennec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Frank Campana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Helgi van de Velde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Samira Bensfia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Sara Bringhen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2020,6,25]]},"reference":[{"key":"24468","unstructured":"Howlader N, Noone A, Krapcho M. SEER Cancer Statistics Review, 1975-2016, National Cancer Institute. 2019. Publisher Full Text|"},{"key":"24469","unstructured":"Willan J, Eyre TA, Sharpley F, Watson C, King AJ, Ramasamy K. Multiple myeloma in the very elderly patient: challenges and solutions. Clin Interv Aging. 2016; 11:423-435."},{"key":"24470","doi-asserted-by":"crossref","unstructured":"Bringhen S, Mateos MV, Zweegman S. Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials. Haematologica. 2013; 98(6):980-987.","DOI":"10.3324\/haematol.2012.075051"},{"key":"24471","doi-asserted-by":"crossref","unstructured":"Dimopoulos MA, Kastritis E, Delimpasi S. Multiple myeloma in octogenarians: clinical features and outcome in the novel agent era. Eur J Haematol. 2012; 89(1):10-15.","DOI":"10.1111\/j.1600-0609.2012.01784.x"},{"key":"24472","doi-asserted-by":"crossref","unstructured":"Deckert J, Wetzel MC, Bartle LM. SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies. Clin Cancer Res. 2014; 20(17):4574-4583.","DOI":"10.1158\/1078-0432.CCR-14-0695"},{"key":"24473","doi-asserted-by":"crossref","unstructured":"Jiang H, Acharya C, An G. SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide. Leukemia. 2016; 30(2):399-408.","DOI":"10.1038\/leu.2015.240"},{"key":"24474","doi-asserted-by":"crossref","unstructured":"Moreno L, Perez C, Zabaleta A. The mechanism of action of the anti-CD38 monoclonal antibody isatuximab in multiple myeloma. Clin Cancer Res. 2019; 25(10):3176-3187.","DOI":"10.1158\/1078-0432.CCR-18-1597"},{"key":"24475","unstructured":"Sanofi. SARCLISA [Package Insert]. 2020."},{"key":"24476","doi-asserted-by":"crossref","unstructured":"Attal M, Richardson PG, Rajkumar SV. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, openlabel, phase 3 study. Lancet. 2019; 394(10214):2096-2107.","DOI":"10.1016\/S0140-6736(19)32556-5"},{"key":"24477","doi-asserted-by":"crossref","unstructured":"Richardson PG, Attal M, Campana F. Isatuximab plus pomalidomide\/ dexamethasone versus pomalidomide\/dexamethasone in relapsed\/refractory multiple myeloma: ICARIA phase III study design. Future Oncol. 2018; 14(11):1035-1047.","DOI":"10.2217\/fon-2017-0616"},{"key":"24478","unstructured":"Anderson KC. Insights into the management of older patients with multiple myeloma. Clin Adv Hematol Oncol. 2019; 17(7):390-392."},{"key":"24479","doi-asserted-by":"crossref","unstructured":"van de Donk N, Richardson PG, Malavasi F. CD38 antibodies in multiple myeloma: back to the future. Blood. 2018; 131(1):13-29.","DOI":"10.1182\/blood-2017-06-740944"},{"key":"24480","doi-asserted-by":"crossref","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S. Revised International Staging System for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015; 33(26):2863-2869.","DOI":"10.1200\/JCO.2015.61.2267"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/9789\/70988","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/9789\/70989","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/9789\/70988","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T09:57:28Z","timestamp":1794045448000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/9789"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,25]]},"references-count":13,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,4,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2020.253450","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6,25]]}}}